Evaluation of an alternative extended-infusion piperacillin–tazobactam dosing strategy for the treatment of gram-negative infections View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2016-10

AUTHORS

Erin M. Winstead, Patrick D. Ratliff, Ryan P. Hickson, Joseph E. Mueller, William R. Judd

ABSTRACT

Introduction To enhance the probability of pharmacodynamic target attainment, piperacillin-tazobactam can be administered as either a continuous or extended-infusion dosage regimen for the treatment of gram-negative infections. Four hour extended-infusions of piperacillin-tazobactam 3.375 g administered intravenously (IV) every 8 h have been widely studied as an alternative to conventional, intermittent dosage regimens with largely favorable outcomes. Objective To assess the clinical and economic impact of a novel 3-h extended-infusion piperacillin-tazobactam dosing strategy for the treatment of gram-negative infections. Setting 433-bed community hospital in Lexington, KY. Methods Retrospective cohort study before and after the implementation of an alternative dosing protocol using a 3-h infusion of piperacillin-tazobactam 3.375 g IV every 6 h. Main outcome measures The primary outcome was in-hospital mortality. Secondary outcomes include length of stay, ICU length of stay, 30-day all-cause hospital readmissions, total cost per admission, complications, and a composite of in-hospital mortality and readmission within 30 days of discharge. Results Readmission within 30 days of hospital discharge was significantly reduced in the extended-infusion arm (1.2 vs. 13.7 %, P = 0.002). A composite endpoint of death or readmission was lower among patients who received the extended-infusion dosing regimen [ORadj 0.20; 95 % CI (0.07-0.57)]. However this was likely driven by reductions in readmission. Conclusion An alternative regimen of extended-infusion piperacillin-tazobactam resulted in a significant reduction in 30-day all-cause hospital readmission. These results indicate that 3-h infusions of piperacillin-tazobactam 3.375 g IV every 6 h may represent a clinically effective alternative to other commonly used regimens and results in fewer readmissions within 30 days. More... »

PAGES

1087-1093

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11096-016-0334-1

DOI

http://dx.doi.org/10.1007/s11096-016-0334-1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1020337346

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/27333796


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anti-Bacterial Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cohort Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Delayed-Action Preparations", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gram-Negative Bacterial Infections", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Infusions, Intravenous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kentucky", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Patient Readmission", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Penicillanic Acid", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Piperacillin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Piperacillin, Tazobactam Drug Combination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Kentucky HealthCare", 
          "id": "https://www.grid.ac/institutes/grid.413001.7", 
          "name": [
            "Department of Pharmacy Services, UK Healthcare, Lexington, KY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Winstead", 
        "givenName": "Erin M.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Department of Pharmacy Services, Saint Joseph Hospital, 1 Saint Joseph Drive, 40504, Lexington, KY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ratliff", 
        "givenName": "Patrick D.", 
        "id": "sg:person.01106265224.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01106265224.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of North Carolina at Chapel Hill", 
          "id": "https://www.grid.ac/institutes/grid.10698.36", 
          "name": [
            "Division of Pharmaceutical Outcomes and Policy, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hickson", 
        "givenName": "Ryan P.", 
        "id": "sg:person.013616143301.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013616143301.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Kentucky HealthCare", 
          "id": "https://www.grid.ac/institutes/grid.413001.7", 
          "name": [
            "Center for Health Services Research, UK Healthcare, Lexington, KY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mueller", 
        "givenName": "Joseph E.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Department of Pharmacy Services, Saint Joseph Hospital, 1 Saint Joseph Drive, 40504, Lexington, KY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Judd", 
        "givenName": "William R.", 
        "id": "sg:person.0651437505.81", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0651437505.81"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1128/aac.02759-14", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001015749"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/cid/cis856", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002078303"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jinf.2012.10.028", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014533074"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1592/phco.31.8.767", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016505273"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1592/phco.22.7.471.33665", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017650477"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1164/rccm.201505-0857oc", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017890408"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/cid/ciu027", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026319506"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1128/aac.00329-06", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026955228"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.clinthera.2012.11.005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031935776"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1086/510590", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040027239"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1128/aac.00521-12", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044546459"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ijantimicag.2008.03.015", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048054236"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.diagmicrobio.2009.03.002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050867179"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1099/jmm.0.073262-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060392447"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2016-10", 
    "datePublishedReg": "2016-10-01", 
    "description": "Introduction To enhance the probability of pharmacodynamic target attainment, piperacillin-tazobactam can be administered as either a continuous or extended-infusion dosage regimen for the treatment of gram-negative infections. Four hour extended-infusions of piperacillin-tazobactam 3.375\u00a0g administered intravenously (IV) every 8\u00a0h have been widely studied as an alternative to conventional, intermittent dosage regimens with largely favorable outcomes. Objective To assess the clinical and economic impact of a novel 3-h extended-infusion piperacillin-tazobactam dosing strategy for the treatment of gram-negative infections. Setting 433-bed community hospital in Lexington, KY. Methods Retrospective cohort study before and after the implementation of an alternative dosing protocol using a 3-h infusion of piperacillin-tazobactam 3.375\u00a0g IV every 6\u00a0h. Main outcome measures The primary outcome was in-hospital mortality. Secondary outcomes include length of stay, ICU length of stay, 30-day all-cause hospital readmissions, total cost per admission, complications, and a composite of in-hospital mortality and readmission within 30\u00a0days of discharge. Results Readmission within 30\u00a0days of hospital discharge was significantly reduced in the extended-infusion arm (1.2 vs. 13.7\u00a0%, P\u00a0=\u00a00.002). A composite endpoint of death or readmission was lower among patients who received the extended-infusion dosing regimen [ORadj 0.20; 95\u00a0% CI (0.07-0.57)]. However this was likely driven by reductions in readmission. Conclusion An alternative regimen of extended-infusion piperacillin-tazobactam resulted in a significant reduction in 30-day all-cause hospital readmission. These results indicate that 3-h infusions of piperacillin-tazobactam 3.375\u00a0g IV every 6\u00a0h may represent a clinically effective alternative to other commonly used regimens and results in fewer readmissions within 30\u00a0days. ", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s11096-016-0334-1", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1044817", 
        "issn": [
          "2210-7703", 
          "2210-7711"
        ], 
        "name": "International Journal of Clinical Pharmacy", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "5", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "38"
      }
    ], 
    "name": "Evaluation of an alternative extended-infusion piperacillin\u2013tazobactam dosing strategy for the treatment of gram-negative infections", 
    "pagination": "1087-1093", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "60e6a3d5b3f49571941f42c3855aa21a0e6320f348936d81da1a8d5ba080bfd4"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "27333796"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101554912"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11096-016-0334-1"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1020337346"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11096-016-0334-1", 
      "https://app.dimensions.ai/details/publication/pub.1020337346"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T12:21", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000362_0000000362/records_87082_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs11096-016-0334-1"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11096-016-0334-1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11096-016-0334-1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11096-016-0334-1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11096-016-0334-1'


 

This table displays all metadata directly associated to this object as RDF triples.

221 TRIPLES      21 PREDICATES      62 URIs      40 LITERALS      28 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11096-016-0334-1 schema:about N04f9785bd39f4ea49ced33b7d99b476f
2 N35b259ee629d49859f605b3b0e97ca21
3 N3842576db24f450ea404818a2a0f9e4b
4 N3d5bc9b64f254b8fb056714dca3ac49b
5 N41a467fe5d8848e88b0ecc322a87c20e
6 N5e333d0494b24d65a2daf36a3e5ea099
7 N75f59a54f2ea4aaba3d39b9aac0bfcf5
8 N7b9bad2afc5946eeb7d6211e94be738f
9 N8a86bbb594a6412dab5e2ce005df114d
10 N97d620db8b0241c7a353de8ab4c897ef
11 Na5527d457bb84b7295ea96320fe1ce04
12 Nb5cabd24db3c4636b1a011b7a98f0ee9
13 Nbfefc10199f14aea86c0b28e82b61b0a
14 Nbff14bd633254cf39d538ea9958ec74e
15 Ncb0303d50ea54322abf893248c85961e
16 Nf0a093864d1c4b1f96f69e07f3c32f6c
17 Nf5d681b270ac4c47a01de2411b3b2bce
18 Nfd6a7ef0e21641c19778f4cf9e109191
19 Nff1455603d424ce0af87e5605d75501d
20 anzsrc-for:11
21 anzsrc-for:1103
22 schema:author N87a038c61fd249ff80268a74b1982198
23 schema:citation https://doi.org/10.1016/j.clinthera.2012.11.005
24 https://doi.org/10.1016/j.diagmicrobio.2009.03.002
25 https://doi.org/10.1016/j.ijantimicag.2008.03.015
26 https://doi.org/10.1016/j.jinf.2012.10.028
27 https://doi.org/10.1086/510590
28 https://doi.org/10.1093/cid/cis856
29 https://doi.org/10.1093/cid/ciu027
30 https://doi.org/10.1099/jmm.0.073262-0
31 https://doi.org/10.1128/aac.00329-06
32 https://doi.org/10.1128/aac.00521-12
33 https://doi.org/10.1128/aac.02759-14
34 https://doi.org/10.1164/rccm.201505-0857oc
35 https://doi.org/10.1592/phco.22.7.471.33665
36 https://doi.org/10.1592/phco.31.8.767
37 schema:datePublished 2016-10
38 schema:datePublishedReg 2016-10-01
39 schema:description Introduction To enhance the probability of pharmacodynamic target attainment, piperacillin-tazobactam can be administered as either a continuous or extended-infusion dosage regimen for the treatment of gram-negative infections. Four hour extended-infusions of piperacillin-tazobactam 3.375 g administered intravenously (IV) every 8 h have been widely studied as an alternative to conventional, intermittent dosage regimens with largely favorable outcomes. Objective To assess the clinical and economic impact of a novel 3-h extended-infusion piperacillin-tazobactam dosing strategy for the treatment of gram-negative infections. Setting 433-bed community hospital in Lexington, KY. Methods Retrospective cohort study before and after the implementation of an alternative dosing protocol using a 3-h infusion of piperacillin-tazobactam 3.375 g IV every 6 h. Main outcome measures The primary outcome was in-hospital mortality. Secondary outcomes include length of stay, ICU length of stay, 30-day all-cause hospital readmissions, total cost per admission, complications, and a composite of in-hospital mortality and readmission within 30 days of discharge. Results Readmission within 30 days of hospital discharge was significantly reduced in the extended-infusion arm (1.2 vs. 13.7 %, P = 0.002). A composite endpoint of death or readmission was lower among patients who received the extended-infusion dosing regimen [ORadj 0.20; 95 % CI (0.07-0.57)]. However this was likely driven by reductions in readmission. Conclusion An alternative regimen of extended-infusion piperacillin-tazobactam resulted in a significant reduction in 30-day all-cause hospital readmission. These results indicate that 3-h infusions of piperacillin-tazobactam 3.375 g IV every 6 h may represent a clinically effective alternative to other commonly used regimens and results in fewer readmissions within 30 days.
40 schema:genre research_article
41 schema:inLanguage en
42 schema:isAccessibleForFree false
43 schema:isPartOf N8d9a88b6345f4aa79a51823462a21bdb
44 Nf3e0de2799a94e3092ce8370db41d327
45 sg:journal.1044817
46 schema:name Evaluation of an alternative extended-infusion piperacillin–tazobactam dosing strategy for the treatment of gram-negative infections
47 schema:pagination 1087-1093
48 schema:productId N156ca98294984210acd897eae573e6e4
49 N5632edfd9e9e45699fdb768e6dc2080d
50 N7a022d0f472e4a02b37bc987ffcda24a
51 Ne344d42047c8489589e2496e873f8796
52 Nf8b8639fccef4087a6d742e56c16cfc5
53 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020337346
54 https://doi.org/10.1007/s11096-016-0334-1
55 schema:sdDatePublished 2019-04-11T12:21
56 schema:sdLicense https://scigraph.springernature.com/explorer/license/
57 schema:sdPublisher N8450f738396f4edf878d59ff03cf7b95
58 schema:url https://link.springer.com/10.1007%2Fs11096-016-0334-1
59 sgo:license sg:explorer/license/
60 sgo:sdDataset articles
61 rdf:type schema:ScholarlyArticle
62 N0279fcef13fd42c4bc7b7b268cad1b3a rdf:first sg:person.01106265224.01
63 rdf:rest Na18578c9d20a42028ae241b3ac5e9e96
64 N04f9785bd39f4ea49ced33b7d99b476f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
65 schema:name Female
66 rdf:type schema:DefinedTerm
67 N0756726015a548a094968a473dbb36d5 rdf:first sg:person.0651437505.81
68 rdf:rest rdf:nil
69 N156ca98294984210acd897eae573e6e4 schema:name pubmed_id
70 schema:value 27333796
71 rdf:type schema:PropertyValue
72 N273c623e597348e79a29d13639084b8e schema:affiliation https://www.grid.ac/institutes/grid.413001.7
73 schema:familyName Winstead
74 schema:givenName Erin M.
75 rdf:type schema:Person
76 N341572c7ce5e4cd5ab5de615daf07a24 schema:name Department of Pharmacy Services, Saint Joseph Hospital, 1 Saint Joseph Drive, 40504, Lexington, KY, USA
77 rdf:type schema:Organization
78 N35b259ee629d49859f605b3b0e97ca21 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
79 schema:name Aged, 80 and over
80 rdf:type schema:DefinedTerm
81 N3842576db24f450ea404818a2a0f9e4b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
82 schema:name Middle Aged
83 rdf:type schema:DefinedTerm
84 N3c768fc7216646a09aa29d687517cb45 schema:affiliation https://www.grid.ac/institutes/grid.413001.7
85 schema:familyName Mueller
86 schema:givenName Joseph E.
87 rdf:type schema:Person
88 N3d5bc9b64f254b8fb056714dca3ac49b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
89 schema:name Anti-Bacterial Agents
90 rdf:type schema:DefinedTerm
91 N41a467fe5d8848e88b0ecc322a87c20e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Delayed-Action Preparations
93 rdf:type schema:DefinedTerm
94 N5632edfd9e9e45699fdb768e6dc2080d schema:name dimensions_id
95 schema:value pub.1020337346
96 rdf:type schema:PropertyValue
97 N5e333d0494b24d65a2daf36a3e5ea099 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Aged
99 rdf:type schema:DefinedTerm
100 N67db37bc392642b5b9962e1dc1ab004e schema:name Department of Pharmacy Services, Saint Joseph Hospital, 1 Saint Joseph Drive, 40504, Lexington, KY, USA
101 rdf:type schema:Organization
102 N75f59a54f2ea4aaba3d39b9aac0bfcf5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Treatment Outcome
104 rdf:type schema:DefinedTerm
105 N7a022d0f472e4a02b37bc987ffcda24a schema:name nlm_unique_id
106 schema:value 101554912
107 rdf:type schema:PropertyValue
108 N7b9bad2afc5946eeb7d6211e94be738f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Drug Administration Schedule
110 rdf:type schema:DefinedTerm
111 N8450f738396f4edf878d59ff03cf7b95 schema:name Springer Nature - SN SciGraph project
112 rdf:type schema:Organization
113 N87a038c61fd249ff80268a74b1982198 rdf:first N273c623e597348e79a29d13639084b8e
114 rdf:rest N0279fcef13fd42c4bc7b7b268cad1b3a
115 N8a86bbb594a6412dab5e2ce005df114d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Piperacillin, Tazobactam Drug Combination
117 rdf:type schema:DefinedTerm
118 N8d9a88b6345f4aa79a51823462a21bdb schema:volumeNumber 38
119 rdf:type schema:PublicationVolume
120 N97d620db8b0241c7a353de8ab4c897ef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Gram-Negative Bacterial Infections
122 rdf:type schema:DefinedTerm
123 Na18578c9d20a42028ae241b3ac5e9e96 rdf:first sg:person.013616143301.00
124 rdf:rest Nbcd1ce7e08f342d9abb6538355c9fb19
125 Na5527d457bb84b7295ea96320fe1ce04 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Retrospective Studies
127 rdf:type schema:DefinedTerm
128 Nb5cabd24db3c4636b1a011b7a98f0ee9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Kentucky
130 rdf:type schema:DefinedTerm
131 Nbcd1ce7e08f342d9abb6538355c9fb19 rdf:first N3c768fc7216646a09aa29d687517cb45
132 rdf:rest N0756726015a548a094968a473dbb36d5
133 Nbfefc10199f14aea86c0b28e82b61b0a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Penicillanic Acid
135 rdf:type schema:DefinedTerm
136 Nbff14bd633254cf39d538ea9958ec74e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Cohort Studies
138 rdf:type schema:DefinedTerm
139 Ncb0303d50ea54322abf893248c85961e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Patient Readmission
141 rdf:type schema:DefinedTerm
142 Ne344d42047c8489589e2496e873f8796 schema:name doi
143 schema:value 10.1007/s11096-016-0334-1
144 rdf:type schema:PropertyValue
145 Nf0a093864d1c4b1f96f69e07f3c32f6c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Piperacillin
147 rdf:type schema:DefinedTerm
148 Nf3e0de2799a94e3092ce8370db41d327 schema:issueNumber 5
149 rdf:type schema:PublicationIssue
150 Nf5d681b270ac4c47a01de2411b3b2bce schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Male
152 rdf:type schema:DefinedTerm
153 Nf8b8639fccef4087a6d742e56c16cfc5 schema:name readcube_id
154 schema:value 60e6a3d5b3f49571941f42c3855aa21a0e6320f348936d81da1a8d5ba080bfd4
155 rdf:type schema:PropertyValue
156 Nfd6a7ef0e21641c19778f4cf9e109191 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Humans
158 rdf:type schema:DefinedTerm
159 Nff1455603d424ce0af87e5605d75501d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Infusions, Intravenous
161 rdf:type schema:DefinedTerm
162 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
163 schema:name Medical and Health Sciences
164 rdf:type schema:DefinedTerm
165 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
166 schema:name Clinical Sciences
167 rdf:type schema:DefinedTerm
168 sg:journal.1044817 schema:issn 2210-7703
169 2210-7711
170 schema:name International Journal of Clinical Pharmacy
171 rdf:type schema:Periodical
172 sg:person.01106265224.01 schema:affiliation N341572c7ce5e4cd5ab5de615daf07a24
173 schema:familyName Ratliff
174 schema:givenName Patrick D.
175 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01106265224.01
176 rdf:type schema:Person
177 sg:person.013616143301.00 schema:affiliation https://www.grid.ac/institutes/grid.10698.36
178 schema:familyName Hickson
179 schema:givenName Ryan P.
180 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013616143301.00
181 rdf:type schema:Person
182 sg:person.0651437505.81 schema:affiliation N67db37bc392642b5b9962e1dc1ab004e
183 schema:familyName Judd
184 schema:givenName William R.
185 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0651437505.81
186 rdf:type schema:Person
187 https://doi.org/10.1016/j.clinthera.2012.11.005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031935776
188 rdf:type schema:CreativeWork
189 https://doi.org/10.1016/j.diagmicrobio.2009.03.002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050867179
190 rdf:type schema:CreativeWork
191 https://doi.org/10.1016/j.ijantimicag.2008.03.015 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048054236
192 rdf:type schema:CreativeWork
193 https://doi.org/10.1016/j.jinf.2012.10.028 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014533074
194 rdf:type schema:CreativeWork
195 https://doi.org/10.1086/510590 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040027239
196 rdf:type schema:CreativeWork
197 https://doi.org/10.1093/cid/cis856 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002078303
198 rdf:type schema:CreativeWork
199 https://doi.org/10.1093/cid/ciu027 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026319506
200 rdf:type schema:CreativeWork
201 https://doi.org/10.1099/jmm.0.073262-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1060392447
202 rdf:type schema:CreativeWork
203 https://doi.org/10.1128/aac.00329-06 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026955228
204 rdf:type schema:CreativeWork
205 https://doi.org/10.1128/aac.00521-12 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044546459
206 rdf:type schema:CreativeWork
207 https://doi.org/10.1128/aac.02759-14 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001015749
208 rdf:type schema:CreativeWork
209 https://doi.org/10.1164/rccm.201505-0857oc schema:sameAs https://app.dimensions.ai/details/publication/pub.1017890408
210 rdf:type schema:CreativeWork
211 https://doi.org/10.1592/phco.22.7.471.33665 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017650477
212 rdf:type schema:CreativeWork
213 https://doi.org/10.1592/phco.31.8.767 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016505273
214 rdf:type schema:CreativeWork
215 https://www.grid.ac/institutes/grid.10698.36 schema:alternateName University of North Carolina at Chapel Hill
216 schema:name Division of Pharmaceutical Outcomes and Policy, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
217 rdf:type schema:Organization
218 https://www.grid.ac/institutes/grid.413001.7 schema:alternateName University of Kentucky HealthCare
219 schema:name Center for Health Services Research, UK Healthcare, Lexington, KY, USA
220 Department of Pharmacy Services, UK Healthcare, Lexington, KY, USA
221 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...